Are you over 18 and want to see adult content?
More Annotations
![A complete backup of dominabridget.com](https://www.archivebay.com/archive2/5629b060-c498-4be9-b076-cb345c962264.png)
A complete backup of dominabridget.com
Are you over 18 and want to see adult content?
![A complete backup of cookingwithplants.com](https://www.archivebay.com/archive2/793ae0a8-db09-4307-a964-df22bfd785f1.png)
A complete backup of cookingwithplants.com
Are you over 18 and want to see adult content?
![A complete backup of dominodatalab.com](https://www.archivebay.com/archive2/2eea2c41-07c1-402a-b044-062130c800f6.png)
A complete backup of dominodatalab.com
Are you over 18 and want to see adult content?
![A complete backup of blacksheepvegas.com](https://www.archivebay.com/archive2/88607623-6417-41c9-a9ec-690cd2acf434.png)
A complete backup of blacksheepvegas.com
Are you over 18 and want to see adult content?
![A complete backup of swadeshiupchar.in](https://www.archivebay.com/archive2/04311d4c-8d9c-498b-a0e2-1748e49e3572.png)
A complete backup of swadeshiupchar.in
Are you over 18 and want to see adult content?
![A complete backup of paramountchannel.fr](https://www.archivebay.com/archive2/85de51b8-ba45-479f-bf94-f2baab33d25e.png)
A complete backup of paramountchannel.fr
Are you over 18 and want to see adult content?
![A complete backup of ibuyranking.blogspot.com](https://www.archivebay.com/archive2/2d8949e1-1dbb-481d-9077-e3c34e8b558d.png)
A complete backup of ibuyranking.blogspot.com
Are you over 18 and want to see adult content?
Favourite Annotations
![A complete backup of football-match24.com](https://www.archivebay.com/archive2/6dd1656e-f808-4d1b-aeed-bb758b2f1430.png)
A complete backup of football-match24.com
Are you over 18 and want to see adult content?
![A complete backup of stgeorges-windsor.org](https://www.archivebay.com/archive2/d0a89291-09d0-48cd-8f9d-57cac6d78fae.png)
A complete backup of stgeorges-windsor.org
Are you over 18 and want to see adult content?
![A complete backup of url-encode-decode.com](https://www.archivebay.com/archive2/4fbf9d2a-431f-4a9d-a46e-0ab29e4ceb5d.png)
A complete backup of url-encode-decode.com
Are you over 18 and want to see adult content?
![A complete backup of meiringen-hasliberg.ch](https://www.archivebay.com/archive2/1cfd7ce9-2778-4ffd-9af3-46ae9e94a64e.png)
A complete backup of meiringen-hasliberg.ch
Are you over 18 and want to see adult content?
![A complete backup of fitmomjourney.com](https://www.archivebay.com/archive2/f2615f65-b840-42c3-9d44-4e0c6e4f0243.png)
A complete backup of fitmomjourney.com
Are you over 18 and want to see adult content?
![A complete backup of modelbouwshopper.nl](https://www.archivebay.com/archive2/a5dff8d3-714f-45f3-bdd5-00bf91f7cda0.png)
A complete backup of modelbouwshopper.nl
Are you over 18 and want to see adult content?
![A complete backup of medicalworldnigeria.com](https://www.archivebay.com/archive2/cc506313-6eed-4785-9c3d-b6029668d3f5.png)
A complete backup of medicalworldnigeria.com
Are you over 18 and want to see adult content?
Text
and
PUBLICATIONS
Review publications. May 19, 2016 – Tackling Drug-Resistant Infections Globally: final report and recommendations. This report outlines the Review’s final recommendations. It first discusses the mounting problem of resistance and why action is needed to combat it and then provides an overview of the solutions that the Review thinksshould
ANTIMICROBIAL RESISTANCE: TACKLING A CRISIS FOR THE HEALTH 2 The Review on Antimicrobial Resistance, Chaired by Jim O’Neill 3 The Review on Antimicrobial Resistance, Chaired by Jim O’Neill The Review The UK Prime Minister announced a Review on Antimicrobial Resistance in July, calling for ideas to bring this growing threatunder control.
REDUCING UNNECESSARY USE AND WASTE 1 The precise quantity of antimicrobials used in food production globally is difficult to estimate, but the evidence suggests that it is at least as great as the amount used by humans . TACKLING DRUG-RESISTANT INFECTIONS GLOBALLY tackling drug-resistant infections globally: final report and recommendations the review on antimicrobial resistance chaired by jimo’neill may 2016
FORECAST DIAGNOSTICS FOR ANTIMICROBIAL RESISTANCE (AMR) Forecast diagnostics for antimicrobial resistance (AMR) Authors: Ann Van den Bruel, Philip Turner NIHR Diagnostic Evidence Cooperative Oxford, University of Oxford ANTIMICROBIAL RESISTANCE: WHAT DOES MEDICINE QUALITY HAVE Antimicrobial Resistance and Medicine Quality. Pisani for AMR Review, November 2015 4 Methods The paper is based on two main sources: A desk review of literature related to medicine quality and antimicrobial STOPPING UNNECESSARY USE OF ANTIBIOTICS 3 1. Diagnostic Market Stimulus pots to support a viable market for what is a classic ‘public good’ The use of diagnostics represents a classic example of a ‘public SECURING NEW DRUGS FOR FUTURE GENERATIONS securing new drugs for future generations: the pipeline of antibiotics the review on antimicrobial resistance chaired by jim o’neill may2015
ANALYSIS OF THE POTENTIAL IMPACT OF A POINT-OF-CARE TEST Table 2 Summary of costs implications of more expensive test (Scenario 1 and 3) Heterosexual male MSM Female Total Baseline £69,784,517 20,358,694 £105,826,467 £195,969,677 Scenario HOME | AMR REVIEWHOMEBACKGROUNDINDUSTRYPUBLICATIONSINFOGRAPHICSMEDIA The Review on AMR was jointly supported by the UK Government and Wellcome Trust, although operated with full independence from both. Established as a two-year, time-limited process, the Review engaged widely with international stakeholders to understand and propose solutions to the problem of drug-resistant infections from an economicand
PUBLICATIONS
Review publications. May 19, 2016 – Tackling Drug-Resistant Infections Globally: final report and recommendations. This report outlines the Review’s final recommendations. It first discusses the mounting problem of resistance and why action is needed to combat it and then provides an overview of the solutions that the Review thinksshould
ANTIMICROBIAL RESISTANCE: TACKLING A CRISIS FOR THE HEALTH 2 The Review on Antimicrobial Resistance, Chaired by Jim O’Neill 3 The Review on Antimicrobial Resistance, Chaired by Jim O’Neill The Review The UK Prime Minister announced a Review on Antimicrobial Resistance in July, calling for ideas to bring this growing threatunder control.
REDUCING UNNECESSARY USE AND WASTE 1 The precise quantity of antimicrobials used in food production globally is difficult to estimate, but the evidence suggests that it is at least as great as the amount used by humans . TACKLING DRUG-RESISTANT INFECTIONS GLOBALLY tackling drug-resistant infections globally: final report and recommendations the review on antimicrobial resistance chaired by jimo’neill may 2016
FORECAST DIAGNOSTICS FOR ANTIMICROBIAL RESISTANCE (AMR) Forecast diagnostics for antimicrobial resistance (AMR) Authors: Ann Van den Bruel, Philip Turner NIHR Diagnostic Evidence Cooperative Oxford, University of Oxford ANTIMICROBIAL RESISTANCE: WHAT DOES MEDICINE QUALITY HAVE Antimicrobial Resistance and Medicine Quality. Pisani for AMR Review, November 2015 4 Methods The paper is based on two main sources: A desk review of literature related to medicine quality and antimicrobial STOPPING UNNECESSARY USE OF ANTIBIOTICS 3 1. Diagnostic Market Stimulus pots to support a viable market for what is a classic ‘public good’ The use of diagnostics represents a classic example of a ‘public SECURING NEW DRUGS FOR FUTURE GENERATIONS securing new drugs for future generations: the pipeline of antibiotics the review on antimicrobial resistance chaired by jim o’neill may2015
ANALYSIS OF THE POTENTIAL IMPACT OF A POINT-OF-CARE TEST Table 2 Summary of costs implications of more expensive test (Scenario 1 and 3) Heterosexual male MSM Female Total Baseline £69,784,517 20,358,694 £105,826,467 £195,969,677 ScenarioPUBLICATIONS
Review publications. May 19, 2016 – Tackling Drug-Resistant Infections Globally: final report and recommendations. This report outlines the Review’s final recommendations. It first discusses the mounting problem of resistance and why action is needed to combat it and then provides an overview of the solutions that the Review thinksshould
MEDIA | AMR REVIEW
Press Releases. September 2016- Jim O' Neill responds to G20 summit announcement to tackle antimicrobial resistance. May 2016 - Tackling drug-resistant infections globally: Final report and recommendationsINFOGRAPHICS
These infographics are licenced under the Creative Commons Attribution 4.0 International Public License. Please use the following attribution notice: ‘Review on Antimicrobial Resistance.’REVIEW TEAM
The Review team includes seven core members of staff with expertise in economics and public policy and two experts who advise the Review on the scientific and microeconomics matters at play. INDUSTRY | AMR REVIEW The Review on Antimicrobial Resistance is not a signatory to the Declaration but it has assisted its development and supports its aims. The Review is hosting the Declaration on its website on behalf of the signatory companies. Read the press notice here. Read the industry declaration here. The Declaration was followed in September 2016 by aREVIEW CHAIRMAN
Review chairman. Lord O'Neill of Gatley. Jim O’Neill is an internationally published economist, and until 2013 was Chairman of Goldman Sachs Asset Management, having previously been the organisation’s Head of Economic Research. He joined Goldman Sachs in 1995, after 13 years working in the City of London for the Swiss BankCorporation, the
TERMS OF REFERENCE
The Review is commissioned by, and will report to, the UK Prime Minister. The Review is supported in its work by the UK Department of Health, HM Treasury, and the Foreign and Commonwealth Office, but it operates autonomously of government control. INDEPENDENT REVIEW ON ANTI-MICROBIAL R (AMR) 1 INDEPENDENT REVIEW ON ANTI-MICROBIAL RESISTANCE (AMR) REGULATION-INNOVATION INTERACTIONS IN THE DEVELOPMENT OF ANTIMICROBIAL DRUGS AND DIAGNOSTICS: AN EVALUATION OF DRUG AND IVD INDUSTRY VIEWS Jack Scannell SUPPLEMENTARY REPORT 2 Jack Scannell, Visiting Fellow, Innogen Institute, Science, Technology and Innovation Studies,University of
MANAGING THE SUPPLY CHAIN OF ANTIMICROBIALS 1 1 Morgan D J, Okeke I N, Laxmanirayan R, Perencevich E N, Weisenberg S. Non‑prescription antimicrobial use worldwide: a systematic review. Lancet Infectious Diseases 2011; 11: 692‑701. 2 Orizio G, Merla A, Schulz P J, Gelatti U, 2011, “Quality of online pharmacies and websites selling prescription drugs: A systematic review”, Journal of Medical Internet MODELLING THE ANTIBIOTIC DEVELOPMENT PROCESS classes of antibiotics because most of the drugs in their sample were follow-on products (reflecting patterns of antibiotic research in recent years.)3 What the model does4 Firstly, this model allows the user to choose a high, medium or low setting for all the HOME | AMR REVIEWHOMEBACKGROUNDINDUSTRYPUBLICATIONSINFOGRAPHICSMEDIA The Review on AMR was jointly supported by the UK Government and Wellcome Trust, although operated with full independence from both. Established as a two-year, time-limited process, the Review engaged widely with international stakeholders to understand and propose solutions to the problem of drug-resistant infections from an economicand
PUBLICATIONS
Review publications. May 19, 2016 – Tackling Drug-Resistant Infections Globally: final report and recommendations. This report outlines the Review’s final recommendations. It first discusses the mounting problem of resistance and why action is needed to combat it and then provides an overview of the solutions that the Review thinksshould
ANTIMICROBIAL RESISTANCE: TACKLING A CRISIS FOR THE HEALTH 2 The Review on Antimicrobial Resistance, Chaired by Jim O’Neill 3 The Review on Antimicrobial Resistance, Chaired by Jim O’Neill The Review The UK Prime Minister announced a Review on Antimicrobial Resistance in July, calling for ideas to bring this growing threatunder control.
REDUCING UNNECESSARY USE AND WASTE 1 The precise quantity of antimicrobials used in food production globally is difficult to estimate, but the evidence suggests that it is at least as great as the amount used by humans . TACKLING DRUG-RESISTANT INFECTIONS GLOBALLY tackling drug-resistant infections globally: final report and recommendations the review on antimicrobial resistance chaired by jimo’neill may 2016
FORECAST DIAGNOSTICS FOR ANTIMICROBIAL RESISTANCE (AMR) Forecast diagnostics for antimicrobial resistance (AMR) Authors: Ann Van den Bruel, Philip Turner NIHR Diagnostic Evidence Cooperative Oxford, University of Oxford ANTIMICROBIAL RESISTANCE: WHAT DOES MEDICINE QUALITY HAVE Antimicrobial Resistance and Medicine Quality. Pisani for AMR Review, November 2015 4 Methods The paper is based on two main sources: A desk review of literature related to medicine quality and antimicrobial SECURING NEW DRUGS FOR FUTURE GENERATIONS securing new drugs for future generations: the pipeline of antibiotics the review on antimicrobial resistance chaired by jim o’neill may2015
MODELLING THE ANTIBIOTIC DEVELOPMENT PROCESS classes of antibiotics because most of the drugs in their sample were follow-on products (reflecting patterns of antibiotic research in recent years.)3 What the model does4 Firstly, this model allows the user to choose a high, medium or low setting for all the ANALYSIS OF THE POTENTIAL IMPACT OF A POINT-OF-CARE TEST Table 2 Summary of costs implications of more expensive test (Scenario 1 and 3) Heterosexual male MSM Female Total Baseline £69,784,517 20,358,694 £105,826,467 £195,969,677 Scenario HOME | AMR REVIEWHOMEBACKGROUNDINDUSTRYPUBLICATIONSINFOGRAPHICSMEDIA The Review on AMR was jointly supported by the UK Government and Wellcome Trust, although operated with full independence from both. Established as a two-year, time-limited process, the Review engaged widely with international stakeholders to understand and propose solutions to the problem of drug-resistant infections from an economicand
PUBLICATIONS
Review publications. May 19, 2016 – Tackling Drug-Resistant Infections Globally: final report and recommendations. This report outlines the Review’s final recommendations. It first discusses the mounting problem of resistance and why action is needed to combat it and then provides an overview of the solutions that the Review thinksshould
ANTIMICROBIAL RESISTANCE: TACKLING A CRISIS FOR THE HEALTH 2 The Review on Antimicrobial Resistance, Chaired by Jim O’Neill 3 The Review on Antimicrobial Resistance, Chaired by Jim O’Neill The Review The UK Prime Minister announced a Review on Antimicrobial Resistance in July, calling for ideas to bring this growing threatunder control.
REDUCING UNNECESSARY USE AND WASTE 4 The work of the Review The Review on AMR was commissioned by the British Prime Minister, and is hosted by the Wellcome Trust . It is tasked with recommending, by the summer of 2016, a comprehensive TACKLING DRUG-RESISTANT INFECTIONS GLOBALLY tackling drug-resistant infections globally: final report and recommendations the review on antimicrobial resistance chaired by jimo’neill may 2016
FORECAST DIAGNOSTICS FOR ANTIMICROBIAL RESISTANCE (AMR) Forecast diagnostics for antimicrobial resistance (AMR) Authors: Ann Van den Bruel, Philip Turner NIHR Diagnostic Evidence Cooperative Oxford, University of Oxford ANTIMICROBIAL RESISTANCE: WHAT DOES MEDICINE QUALITY HAVE Antimicrobial Resistance and Medicine Quality. Pisani for AMR Review, November 2015 4 Methods The paper is based on two main sources: A desk review of literature related to medicine quality and antimicrobial SECURING NEW DRUGS FOR FUTURE GENERATIONS securing new drugs for future generations: the pipeline of antibiotics the review on antimicrobial resistance chaired by jim o’neill may2015
MODELLING THE ANTIBIOTIC DEVELOPMENT PROCESS classes of antibiotics because most of the drugs in their sample were follow-on products (reflecting patterns of antibiotic research in recent years.)3 What the model does4 Firstly, this model allows the user to choose a high, medium or low setting for all the ANALYSIS OF THE POTENTIAL IMPACT OF A POINT-OF-CARE TEST Table 2 Summary of costs implications of more expensive test (Scenario 1 and 3) Heterosexual male MSM Female Total Baseline £69,784,517 20,358,694 £105,826,467 £195,969,677 Scenario BACKGROUND | AMR REVIEW Background | AMR Review. Historical Context. The discovery of antibiotics and their widespread availability revolutionised healthcare after the Second World War. They underpin many of the greatest medical advances of the 20th century. But bacteria and pathogens have always evolved to resist the new drugs that scientists invent to combat them. REVIEW ADVISORY GROUP An international advisory group provides expertise to the Review. Its current members are: Dr Ren Minghui. Ren Minghui is currently the Director-General for International Cooperation, China National Health and Family Planning. He served on the Executive Board of WHO and the Board of Global Fund to Fight HIV/AIDS, TB and Malaria for many years.Dr.
INFOGRAPHICS
These infographics are licenced under the Creative Commons Attribution 4.0 International Public License. Please use the following attribution notice: ‘Review on Antimicrobial Resistance.’ INDUSTRY | AMR REVIEW The Review on Antimicrobial Resistance is not a signatory to the Declaration but it has assisted its development and supports its aims. The Review is hosting the Declaration on its website on behalf of the signatory companies. Read the press notice here. Read the industry declaration here. The Declaration was followed in September 2016 by a STOPPING UNNECESSARY USE OF ANTIBIOTICS 3 1. Diagnostic Market Stimulus pots to support a viable market for what is a classic ‘public good’ The use of diagnostics represents a classic example of a ‘publicREVIEW CHAIRMAN
Review chairman. Lord O'Neill of Gatley. Jim O’Neill is an internationally published economist, and until 2013 was Chairman of Goldman Sachs Asset Management, having previously been the organisation’s Head of Economic Research. He joined Goldman Sachs in 1995, after 13 years working in the City of London for the Swiss BankCorporation, the
TERMS OF REFERENCE
The Review is commissioned by, and will report to, the UK Prime Minister. The Review is supported in its work by the UK Department of Health, HM Treasury, and the Foreign and Commonwealth Office, but it operates autonomously of government control. INDEPENDENT REVIEW ON ANTI-MICROBIAL R (AMR) 1 INDEPENDENT REVIEW ON ANTI-MICROBIAL RESISTANCE (AMR) REGULATION-INNOVATION INTERACTIONS IN THE DEVELOPMENT OF ANTIMICROBIAL DRUGS AND DIAGNOSTICS: AN EVALUATION OF DRUG AND IVD INDUSTRY VIEWS Jack Scannell SUPPLEMENTARY REPORT 2 Jack Scannell, Visiting Fellow, Innogen Institute, Science, Technology and Innovation Studies,University of
ANALYSIS OF THE POTENTIAL IMPACT OF A POINT-OF-CARE TEST Table 2 Summary of costs implications of more expensive test (Scenario 1 and 3) Heterosexual male MSM Female Total Baseline £69,784,517 20,358,694 £105,826,467 £195,969,677 Scenario PRESS NOTICE FOR VACCINES AND ALTERNATIVES PAPERWEB VIEW Jim O’Neill calls for wider use of vaccines and alternative approaches to tackle drug-resistant infections. Vaccines and other alternatives . can play . a vital . role in. tackl. ing. the rise of . drug-resistan. t infections. As . existing. antibiotics become less effective, because microbes evolve to resist them, we need to usethose that we have
HOME | AMR REVIEWHOMEBACKGROUNDINDUSTRYPUBLICATIONSINFOGRAPHICSMEDIA The Review on AMR was jointly supported by the UK Government and Wellcome Trust, although operated with full independence from both. Established as a two-year, time-limited process, the Review engaged widely with international stakeholders to understand and propose solutions to the problem of drug-resistant infections from an economicand
PUBLICATIONS
Review publications. May 19, 2016 – Tackling Drug-Resistant Infections Globally: final report and recommendations. This report outlines the Review’s final recommendations. It first discusses the mounting problem of resistance and why action is needed to combat it and then provides an overview of the solutions that the Review thinksshould
INFOGRAPHICS
These infographics are licenced under the Creative Commons Attribution 4.0 International Public License. Please use the following attribution notice: ‘Review on Antimicrobial Resistance.’ INDUSTRY | AMR REVIEW The Review on Antimicrobial Resistance is not a signatory to the Declaration but it has assisted its development and supports its aims. The Review is hosting the Declaration on its website on behalf of the signatory companies. Read the press notice here. Read the industry declaration here. The Declaration was followed in September 2016 by a REDUCING UNNECESSARY USE AND WASTE 1 The precise quantity of antimicrobials used in food production globally is difficult to estimate, but the evidence suggests that it is at least as great as the amount used by humans . ANTIMICROBIAL RESISTANCE: TACKLING A CRISIS FOR THE HEALTH 2 The Review on Antimicrobial Resistance, Chaired by Jim O’Neill 3 The Review on Antimicrobial Resistance, Chaired by Jim O’Neill The Review The UK Prime Minister announced a Review on Antimicrobial Resistance in July, calling for ideas to bring this growing threatunder control.
TACKLING DRUG-RESISTANT INFECTIONS GLOBALLY tackling drug-resistant infections globally: final report and recommendations the review on antimicrobial resistance chaired by jimo’neill may 2016
SECURING NEW DRUGS FOR FUTURE GENERATIONS securing new drugs for future generations: the pipeline of antibiotics the review on antimicrobial resistance chaired by jim o’neill may2015
ANTIMICROBIAL RESISTANCE: WHAT DOES MEDICINE QUALITY HAVE Antimicrobial Resistance and Medicine Quality. Pisani for AMR Review, November 2015 4 Methods The paper is based on two main sources: A desk review of literature related to medicine quality and antimicrobial ANALYSIS OF THE POTENTIAL IMPACT OF A POINT-OF-CARE TEST Table 2 Summary of costs implications of more expensive test (Scenario 1 and 3) Heterosexual male MSM Female Total Baseline £69,784,517 20,358,694 £105,826,467 £195,969,677 Scenario HOME | AMR REVIEWHOMEBACKGROUNDINDUSTRYPUBLICATIONSINFOGRAPHICSMEDIA The Review on AMR was jointly supported by the UK Government and Wellcome Trust, although operated with full independence from both. Established as a two-year, time-limited process, the Review engaged widely with international stakeholders to understand and propose solutions to the problem of drug-resistant infections from an economicand
PUBLICATIONS
Review publications. May 19, 2016 – Tackling Drug-Resistant Infections Globally: final report and recommendations. This report outlines the Review’s final recommendations. It first discusses the mounting problem of resistance and why action is needed to combat it and then provides an overview of the solutions that the Review thinksshould
INFOGRAPHICS
These infographics are licenced under the Creative Commons Attribution 4.0 International Public License. Please use the following attribution notice: ‘Review on Antimicrobial Resistance.’ INDUSTRY | AMR REVIEW The Review on Antimicrobial Resistance is not a signatory to the Declaration but it has assisted its development and supports its aims. The Review is hosting the Declaration on its website on behalf of the signatory companies. Read the press notice here. Read the industry declaration here. The Declaration was followed in September 2016 by a REDUCING UNNECESSARY USE AND WASTE 1 The precise quantity of antimicrobials used in food production globally is difficult to estimate, but the evidence suggests that it is at least as great as the amount used by humans . ANTIMICROBIAL RESISTANCE: TACKLING A CRISIS FOR THE HEALTH 2 The Review on Antimicrobial Resistance, Chaired by Jim O’Neill 3 The Review on Antimicrobial Resistance, Chaired by Jim O’Neill The Review The UK Prime Minister announced a Review on Antimicrobial Resistance in July, calling for ideas to bring this growing threatunder control.
TACKLING DRUG-RESISTANT INFECTIONS GLOBALLY tackling drug-resistant infections globally: final report and recommendations the review on antimicrobial resistance chaired by jimo’neill may 2016
SECURING NEW DRUGS FOR FUTURE GENERATIONS securing new drugs for future generations: the pipeline of antibiotics the review on antimicrobial resistance chaired by jim o’neill may2015
ANTIMICROBIAL RESISTANCE: WHAT DOES MEDICINE QUALITY HAVE Antimicrobial Resistance and Medicine Quality. Pisani for AMR Review, November 2015 4 Methods The paper is based on two main sources: A desk review of literature related to medicine quality and antimicrobial ANALYSIS OF THE POTENTIAL IMPACT OF A POINT-OF-CARE TEST Table 2 Summary of costs implications of more expensive test (Scenario 1 and 3) Heterosexual male MSM Female Total Baseline £69,784,517 20,358,694 £105,826,467 £195,969,677 ScenarioMEDIA | AMR REVIEW
Press Releases. September 2016- Jim O' Neill responds to G20 summit announcement to tackle antimicrobial resistance. May 2016 - Tackling drug-resistant infections globally: Final report and recommendationsREVIEW TEAM
The Review team includes seven core members of staff with expertise in economics and public policy and two experts who advise the Review on the scientific and microeconomics matters at play. BACKGROUND | AMR REVIEW Background | AMR Review. Historical Context. The discovery of antibiotics and their widespread availability revolutionised healthcare after the Second World War. They underpin many of the greatest medical advances of the 20th century. But bacteria and pathogens have always evolved to resist the new drugs that scientists invent to combat them. REVIEW ADVISORY GROUP An international advisory group provides expertise to the Review. Its current members are: Dr Ren Minghui. Ren Minghui is currently the Director-General for International Cooperation, China National Health and Family Planning. He served on the Executive Board of WHO and the Board of Global Fund to Fight HIV/AIDS, TB and Malaria for many years.Dr.
REVIEW CHAIRMAN
Review chairman. Lord O'Neill of Gatley. Jim O’Neill is an internationally published economist, and until 2013 was Chairman of Goldman Sachs Asset Management, having previously been the organisation’s Head of Economic Research. He joined Goldman Sachs in 1995, after 13 years working in the City of London for the Swiss BankCorporation, the
STOPPING UNNECESSARY USE OF ANTIBIOTICS 3 1. Diagnostic Market Stimulus pots to support a viable market for what is a classic ‘public good’ The use of diagnostics represents a classic example of a ‘public INDEPENDENT REVIEW ON ANTI-MICROBIAL R (AMR) 1 INDEPENDENT REVIEW ON ANTI-MICROBIAL RESISTANCE (AMR) REGULATION-INNOVATION INTERACTIONS IN THE DEVELOPMENT OF ANTIMICROBIAL DRUGS AND DIAGNOSTICS: AN EVALUATION OF DRUG AND IVD INDUSTRY VIEWS Jack Scannell SUPPLEMENTARY REPORT 2 Jack Scannell, Visiting Fellow, Innogen Institute, Science, Technology and Innovation Studies,University of
FORECAST DIAGNOSTICS FOR ANTIMICROBIAL RESISTANCE (AMR) Forecast diagnostics for antimicrobial resistance (AMR) Authors: Ann Van den Bruel, Philip Turner NIHR Diagnostic Evidence Cooperative Oxford, University of Oxford A CRITICAL ASSESSMENT OF INCENTIVE STRATEGIES FOR A Critical Assessment of Incentive Strategies for Development of Novel Antibiotics Matthew Renwick, 1David Brogan, & Elias Mossialos LSE Health, London School of Economics and Political Science MANAGING THE SUPPLY CHAIN OF ANTIMICROBIALS 1 1 Morgan D J, Okeke I N, Laxmanirayan R, Perencevich E N, Weisenberg S. Non‑prescription antimicrobial use worldwide: a systematic review. Lancet Infectious Diseases 2011; 11: 692‑701. 2 Orizio G, Merla A, Schulz P J, Gelatti U, 2011, “Quality of online pharmacies and websites selling prescription drugs: A systematic review”, Journal of Medical InternetHOME | AMR
REVIEWHOMEBACKGROUNDINDUSTRYPUBLICATIONSINFOGRAPHICSMEDIAAMR EMPLOYEE “The Review on Antimicrobial Resistance (AMR), was commissioned in July 2014 by the UK Prime Minister, who asked economist Jim O’Neill to analyse the global problem of rising drug resistance and propose concrete actions to tackle it internationally.PUBLICATIONS
November 20, 2015 - Safe, Secure and Controlled: Managing the Supply Chain of Antimicrobials This report examines two specific aspects of the AMR problem: the online sale of antimicrobials without prescription, and the supply of poor-quality and falsified antimicrobial drugs.INFOGRAPHICS
These infographics are licenced under the Creative Commons Attribution 4.0 International Public License. Please use the following attribution notice: ‘Review on Antimicrobial Resistance.’ INDUSTRY | AMR REVIEWAMR REVIEWAMR MEDICAL REVIEWANTIBIOTIC RESISTANCE REVIEWAMR REPORTAMR EMPLOYEEAMR REVIEWS Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance. On January 21, 2016, the Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance was launched at an event at the World Economic Forum in Davos, Switzerland.. When published in January 2016, the Declaration had been drafted REDUCING UNNECESSARY USE AND WASTE 1 The precise quantity of antimicrobials used in food production globally is difficult to estimate, but the evidence suggests that it is at least as great as the amount used by humans . ANTIMICROBIAL RESISTANCE: TACKLING A CRISIS FOR THE HEALTH 2 The Review on Antimicrobial Resistance, Chaired by Jim O’Neill 3 The Review on Antimicrobial Resistance, Chaired by Jim O’Neill The Review The UK Prime Minister announced a Review on Antimicrobial Resistance in July, calling for ideas to bring this growing threatunder control.
TACKLING DRUG-RESISTANT INFECTIONS GLOBALLY tackling drug-resistant infections globally: final report and recommendations the review on antimicrobial resistance chaired by jimo’neill may 2016
SECURING NEW DRUGS FOR FUTURE GENERATIONS securing new drugs for future generations: the pipeline of antibiotics the review on antimicrobial resistance chaired by jim o’neill may2015
ANTIMICROBIAL RESISTANCE: WHAT DOES MEDICINE QUALITY HAVE Antimicrobial Resistance and Medicine Quality. Pisani for AMR Review, November 2015 4 Methods The paper is based on two main sources: A desk review of literature related to medicine quality and antimicrobial ANALYSIS OF THE POTENTIAL IMPACT OF A POINT-OF-CARE TEST Table 2 Summary of costs implications of more expensive test (Scenario 1 and 3) Heterosexual male MSM Female Total Baseline £69,784,517 20,358,694 £105,826,467 £195,969,677 ScenarioHOME | AMR
REVIEWHOMEBACKGROUNDINDUSTRYPUBLICATIONSINFOGRAPHICSMEDIAAMR EMPLOYEE “The Review on Antimicrobial Resistance (AMR), was commissioned in July 2014 by the UK Prime Minister, who asked economist Jim O’Neill to analyse the global problem of rising drug resistance and propose concrete actions to tackle it internationally.PUBLICATIONS
November 20, 2015 - Safe, Secure and Controlled: Managing the Supply Chain of Antimicrobials This report examines two specific aspects of the AMR problem: the online sale of antimicrobials without prescription, and the supply of poor-quality and falsified antimicrobial drugs.INFOGRAPHICS
These infographics are licenced under the Creative Commons Attribution 4.0 International Public License. Please use the following attribution notice: ‘Review on Antimicrobial Resistance.’ INDUSTRY | AMR REVIEWAMR REVIEWAMR MEDICAL REVIEWANTIBIOTIC RESISTANCE REVIEWAMR REPORTAMR EMPLOYEEAMR REVIEWS Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance. On January 21, 2016, the Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance was launched at an event at the World Economic Forum in Davos, Switzerland.. When published in January 2016, the Declaration had been drafted REDUCING UNNECESSARY USE AND WASTE 1 The precise quantity of antimicrobials used in food production globally is difficult to estimate, but the evidence suggests that it is at least as great as the amount used by humans . ANTIMICROBIAL RESISTANCE: TACKLING A CRISIS FOR THE HEALTH 2 The Review on Antimicrobial Resistance, Chaired by Jim O’Neill 3 The Review on Antimicrobial Resistance, Chaired by Jim O’Neill The Review The UK Prime Minister announced a Review on Antimicrobial Resistance in July, calling for ideas to bring this growing threatunder control.
TACKLING DRUG-RESISTANT INFECTIONS GLOBALLY tackling drug-resistant infections globally: final report and recommendations the review on antimicrobial resistance chaired by jimo’neill may 2016
SECURING NEW DRUGS FOR FUTURE GENERATIONS securing new drugs for future generations: the pipeline of antibiotics the review on antimicrobial resistance chaired by jim o’neill may2015
ANTIMICROBIAL RESISTANCE: WHAT DOES MEDICINE QUALITY HAVE Antimicrobial Resistance and Medicine Quality. Pisani for AMR Review, November 2015 4 Methods The paper is based on two main sources: A desk review of literature related to medicine quality and antimicrobial ANALYSIS OF THE POTENTIAL IMPACT OF A POINT-OF-CARE TEST Table 2 Summary of costs implications of more expensive test (Scenario 1 and 3) Heterosexual male MSM Female Total Baseline £69,784,517 20,358,694 £105,826,467 £195,969,677 ScenarioMEDIA | AMR REVIEW
Press Releases. September 2016- Jim O' Neill responds to G20 summit announcement to tackle antimicrobial resistance. May 2016 - Tackling drug-resistant infections globally: Final report and recommendationsREVIEW TEAM
The Review team includes seven core members of staff with expertise in economics and public policy and two experts who advise the Review on the scientific and microeconomics matters at play. BACKGROUND | AMR REVIEW Historical Context. The discovery of antibiotics and their widespread availability revolutionised healthcare after the Second World War. They underpin many of the greatest medical advances of the 20thcentury.
REVIEW ADVISORY GROUP An international advisory group provides expertise to the Review. Its current members are: Dr Ren Minghui Ren Minghui is currently the Director-General for International Cooperation, China National Health and Family Planning.REVIEW CHAIRMAN
Lord O'Neill of Gatley Jim O’Neill is an internationally published economist, and until 2013 was Chairman of Goldman Sachs Asset Management, having previously been STOPPING UNNECESSARY USE OF ANTIBIOTICS 3 1. Diagnostic Market Stimulus pots to support a viable market for what is a classic ‘public good’ The use of diagnostics represents a classic example of a ‘public INDEPENDENT REVIEW ON ANTI-MICROBIAL R (AMR) 1 INDEPENDENT REVIEW ON ANTI-MICROBIAL RESISTANCE (AMR) REGULATION-INNOVATION INTERACTIONS IN THE DEVELOPMENT OF ANTIMICROBIAL DRUGS AND DIAGNOSTICS: AN EVALUATION OF DRUG AND IVD INDUSTRY VIEWS Jack Scannell SUPPLEMENTARY REPORT 2 Jack Scannell, Visiting Fellow, Innogen Institute, Science, Technology and Innovation Studies,University of
FORECAST DIAGNOSTICS FOR ANTIMICROBIAL RESISTANCE (AMR) Forecast diagnostics for antimicrobial resistance (AMR) Authors: Ann Van den Bruel, Philip Turner NIHR Diagnostic Evidence Cooperative Oxford, University of Oxford A CRITICAL ASSESSMENT OF INCENTIVE STRATEGIES FOR A Critical Assessment of Incentive Strategies for Development of Novel Antibiotics Matthew Renwick, 1David Brogan, & Elias Mossialos LSE Health, London School of Economics and Political Science MANAGING THE SUPPLY CHAIN OF ANTIMICROBIALS 1 1 Morgan D J, Okeke I N, Laxmanirayan R, Perencevich E N, Weisenberg S. Non‑prescription antimicrobial use worldwide: a systematic review. Lancet Infectious Diseases 2011; 11: 692‑701. 2 Orizio G, Merla A, Schulz P J, Gelatti U, 2011, “Quality of online pharmacies and websites selling prescription drugs: A systematic review”, Journal of Medical Internet Skip to main contentAMR Review
* Home
* Background
* Industry
* Publications
* Infographics
* Media
* About us
* Terms of reference* Review chairman
* Review advisory group* Review team
HOME
The Review on Antimicrobial Resistance has now completed its work. The content of this website is frozen as an archive of the Review’s work, and will not be updated further. The legacy of the Review will be maintained by its sponsor organisations, the Wellcome Trust and the UK Department of Health. For queries about the legacy of the Review, or for media enquiries for the Review’s former chair, Jim O’Neill only, please contact, please contact info@amr-review.org. “The Review on Antimicrobial Resistance (AMR), was commissioned in July 2014 by the UK Prime Minister, who asked economist Jim O’Neill to analyse the global problem of rising drug resistance and propose concrete actions to tackle it internationally. The Review on AMR was jointly supported by the UK Government and Wellcome Trust, although operated with full independence from both. Established as a two-year, time-limited process, the Review engaged widely with international stakeholders to understand and propose solutions to the problem of drug-resistant infections from an economic and social perspective, and produced its final report and recommendations in the summer of 2016. > "If we fail to act, we are looking at an almost unthinkable scenario > where antibiotics no longer work and we are cast back into the dark > ages of medicine" – David Cameron, former UK Prime Minister The real implications of spreading drug resistance will be felt the world over, with developing countries and large emerging nations bearing the brunt of this problem. Routine surgeries and minor infections will become life- threatening once again and the hard won victories against infectious diseases of the last fifty years will be jeopardised. Hospital stays and expenses, for both public health care providers and for out of –pocket payers will increase significantly. Drug resistant infections are already on the rise with numbers suggesting that up to 50,000 lives are lost each year to antibiotic-resistant infections in Europe and the US alone. Globally, at least 700,000 die each year of drug resistance in illnesses such as bacterial infections, malaria, HIV/AIDS or tuberculosis. > “We have reached a critical point and must act now on a global > scale to slow down antimicrobial resistance” – Professor Dame > Sally Davies, UK Chief Medical Officer May 19, 2016 – Tackling Drug-Resistant Infections Globally: final report and recommendations This report outlines the Review’s final recommendations. It first discusses the mounting problem of resistance and why action is needed to combat it and then provides an overview of the solutions that the Review thinks should be implemented to curtail unnecessary use and increase the supply of new antimicrobials. It then looks at the role of public awareness campaigns, the need to improve sanitation and hygiene, reduce pollution from agriculture and the environment, improve global surveillance, introduce rapid diagnostics and vaccines, the need to increase the number of people in this area, and use of market entry rewards and an innovation fund to generate more drugs. Finally the paper examines how these solutions can be funded and looks at ways to build political consensus around them. SUPPORTING DOCUMENTS * Commissioned study by Dr. Nimalan Arinaminpathy the impact of diagnostics and new treatments against TB main report.
* Commissioned study by the Foundation for Innovative New Diagnostics (FIND), into the future of TB diagnostics main report.
* Commissioned paper by ReAct-Action on Antibiotic Resistance Strategic Policy Program and Center for a Livable Future in the Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health main report.
* Commissioned study by Katy Turner et al. into the impact of rapid diagnostics against gonorrhea main reportand
the model used
.
* Study by LSE Master’s in Public Administration students on the cost and benefit of WASH interventions in Brazil, India, Nigeria and Indonesia main report . * Commissioned study by NIHR Diagnostic Evidence Cooperative Oxford, into the future of diagnostics for antimicrobials main report.
* Commissioned study by Pierre Nouvellet et al. into the impact of new drugs and better diagnostics in the treatment of _E. Coli_ mainreport.
Translations of the introduction and executive summary are available in the following languages; Arabic, Chinese
, French
, Japanese
, Portuguese
and Spanish
.
Follow @ReviewOnAMR on twitterCONTACT US
Gibbs Building, 215 Euston Road,London, NW1 2BE
info@amr-review.org
WE USE COOKIES ON THIS SITE TO ENHANCE YOUR EXPERIENCE By clicking any link on this page you are giving your consent for usto set cookies.
Yes, I agree No, I want to find out moreDetails
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0